Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.04% | -38.47% | -1,134.00% | 159.17% | -240.28% |
| Total Depreciation and Amortization | 3.31% | -1.33% | -9.21% | 6.39% | -4.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.32% | 204.14% | 67.40% | -341.01% | 2,497.77% |
| Change in Net Operating Assets | 412.19% | -141.18% | 201.64% | -1,360.00% | -162.46% |
| Cash from Operations | 57.47% | -302.74% | -34.63% | -91.10% | -315.12% |
| Capital Expenditure | 95.31% | 43.53% | -- | -- | -152.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 234.71% | -3,704.76% | 11.08% | 5,537.60% | -245.65% |
| Cash from Investing | 234.48% | -3,532.56% | 11.07% | 5,532.35% | -246.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 9.53% | -- |
| Issuance of Common Stock | -100.00% | -99.92% | -99.99% | -- | -37.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 898.37% | -- |
| Cash from Financing | -100.00% | -99.92% | -99.99% | -88.85% | -47.67% |
| Foreign Exchange rate Adjustments | -139.55% | 1,514.29% | 762.86% | 1,210.72% | -83.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 172.59% | -441.70% | -176.34% | 1,757.27% | -250.69% |